Gamma Or Immune Patents (Class 424/85.5)
-
Patent number: 12187787Abstract: The present invention relates to in a monoclonal antibody produced by CpG-DNA, or a functional fragment thereof, the monoclonal antibody, or functional fragment thereof, characterized in that it comprises polypeptide sequence selected from the group consisting of the following polypeptide sequences a heavy chain comprising a complementarity determining region 1 (CDR 1) amino acid sequence consisting of the sequence of SEQ ID NO: 1, a CDR2 consisting of the sequence of SEQ ID NO: 2 and a CDR 3 consisting of the sequence of SEQ ID NO: 3; and a light chain comprising CDR1 amino acid sequence consisting of the sequence of SEQ ID NO: 4, a CDR2 consisting of the sequence of SEQ ID NO: 5 and a CDR 3 consisting of the sequence of SEQ ID NO: 6 and a use of the same.Type: GrantFiled: February 26, 2019Date of Patent: January 7, 2025Assignee: INDUSTRY ACADEMIC COOPERATION FOUNDATION, HALLYM UNIVERSITYInventors: Hyung Joo Kwon, Te Ha Kim, Dong Bum Kim
-
Patent number: 12152074Abstract: The present invention relates to antagonistic antigen binding proteins, a nucleic acid encoding the antagonistic binding protein, a recombinant expression vector comprising the nucleic acid molecule, a host cell comprising the vector, a method of making the antagonistic antigen binding protein, an antagonistic binding protein produced by the method and a pharmaceutical composition comprising the antagonistic binding protein, the nucleic acid or the vector. The present invention further relates to a kit comprising the pharmaceutical composition and use of the antagonistic binding protein in the treatment of cancer and/or chronic infectious diseases.Type: GrantFiled: March 22, 2019Date of Patent: November 26, 2024Assignee: CeingeBiotecnologie Avanzate Franco Salvatore ScarlInventors: Alfredo Nicosia, Nicola Zambrano, Emanuele Sasso, Claudia De Lorenzo
-
Patent number: 12016872Abstract: Compositions and methods for treatment of a condition associated with disease stem cells, and especially cancer stem cells are disclosed. In one aspect, a patient is treated with a stem cell differentiating agent and/or teratogenic pharmaceutical compound to induce one or more destructive pathways in the disease stem cells. Most typically, the destructive pathways include apoptotic pathways, necrotic pathways, and autophagy pathways.Type: GrantFiled: September 16, 2020Date of Patent: June 25, 2024Assignee: Nant Holdings IP, LLCInventor: Patrick Soon-Shiong
-
Patent number: 11975046Abstract: The present invention relates to methods for the treatment of fibrosis. The invention discloses new research which demonstrates that interferon-lambda has directly acting anti-fibrotic effects both in vitro and in vivo and may be used to provide effective new therapies for the treatment of multiple types of fibrosis.Type: GrantFiled: June 29, 2023Date of Patent: May 7, 2024Assignees: UCB BIOPHARMA SRL, FIVE PRIME THERAPEUTICS, INC.Inventors: Timothy Scott Johnson, Breda Twomey, Janine Powers, Danielle E. Kellar
-
Patent number: 11747342Abstract: A proteomic expression platform to identify age-related sepsis risk is disclosed using patients with an intra-abdominal infection. A semi-quantitative plasma proteomics workflow was applied which incorporated tandem immuno affinity depletion, iTRAQ labeling, strong cation exchange fractionation, and nanoflow-liquid chromatography coupled to high resolution mass spectrometry. A protein profile was determined that exhibit statistically significant differences in expression levels amongst patients with severe sepsis as a function of age. Representative pathways that are differentially-expressed include, but are not limited to, acute phase response, coagulation signaling, atherosclerosis signaling, lipid metabolism, and production of nitric oxide/reactive oxygen species.Type: GrantFiled: February 17, 2021Date of Patent: September 5, 2023Assignee: University Of Pittsburgh—Of The Commonwealth System Of Higher EducationInventors: John A. Kellum, Zhiyun Cao, Derek Angus, Sachin Purushottam Yende, Rena Angilena Sowell Robinson
-
Patent number: 11447501Abstract: A biphenyl-containing diarylpyrimido compound of formula (I), which is prepared by reacting a 4-chloropyrimidine derivative with a biphenyl derivative in a solvent in the presence of a base. A pharmaceutically-acceptable salt of the compound (I) and a pharmaceutical composition containing the compound (I) or a pharmaceutically-acceptable salt thereof are also provided.Type: GrantFiled: August 5, 2020Date of Patent: September 20, 2022Assignee: Fudan UniveristyInventors: Fener Chen, Yali Sang, Chunlin Zhuang
-
Patent number: 11433137Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: GrantFiled: December 16, 2019Date of Patent: September 6, 2022Assignee: BICYCLERD LIMITEDInventors: Gavin Bennett, Daniel Paul Teufel
-
Patent number: 11370827Abstract: The present invention provides a VWF fragment comprising the D? domain and D3 domain of VWF, a chimeric protein comprising the VWF fragment and a heterologous moiety, or a chimeric protein comprising the VWF fragment and a FVIII protein and methods of using the same. A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein. By preventing or inhibiting binding of endogenous VWF to the FVIII, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.Type: GrantFiled: January 12, 2013Date of Patent: June 28, 2022Assignee: BIOVERATIV THERAPEUTICS INC.Inventors: Ekta Seth Chhabra, Tongyao Liu, Robert T Peters, Haiyan Jiang
-
Patent number: 11331359Abstract: Compositions and methods for treatment of and maintaining the health of the liver are disclosed that include a mixture of plant extracts, wherein the plant extracts comprise at least one Artemisia extract, at least one Aloe gel powder, and at least one Schizandra extract. Compositions and methods for treatment of and maintaining the health of the liver are disclosed that include a mixture of plant extracts, wherein the plant extracts comprise at least one Artemisia extract enriched for at least one polymer or biopolymer, at least one Aloe gel powder enriched for at least one chromone, and at least one Schizandra extract enriched for at least one lignan and organic acid.Type: GrantFiled: July 12, 2016Date of Patent: May 17, 2022Assignee: Unigen, Inc.Inventors: Qi Jia, Mesfin Yimam, Ping Jiao, Mei Feng Hong, Breanna Moore
-
Patent number: 11154550Abstract: Provided is a method of treating and/or preventing Wolfram Syndrome (WS)-related neurodegeneration (i.e. of Wolfram Syndrome-Associated Neuronal Degeneration), by increasing the expression and/or functional activity of p21. A method of screening for pharmacological agents useful in treating and/or preventing such conditions is also provided.Type: GrantFiled: September 27, 2013Date of Patent: October 26, 2021Assignee: The University of BirminghamInventors: Zsuzsanna Nagy, Timothy Barrett
-
Patent number: 11135162Abstract: The invention relates to a pharmaceutical composition in the form of an aqueous solution, preferably a syrup, containing inosine pranobex and zinc gluconate, characterised in that it contains a sweetener selected from the group of disaccharides, preferably sucrose or/and from the group of polyols, preferably maltitol, a solubilizer from the group of hydroxy alcohols or mixtures thereof, preferably propylene glycol, glycerol, preservatives selected from the group of parahydroxybenzoic acid esters and mixtures thereof, preferably methyl parahydroxybenzoate, propyl parahydroxybenzoate, a sweetener, preferably sodium saccharine or sucralose, and pH regulators in the range from 5.7 to 12.0 preferably aroma, and a method of preparation thereof.Type: GrantFiled: June 21, 2018Date of Patent: October 5, 2021Assignee: AFLOFARM FARMACJA POLSKA SP. Z O. O.Inventors: Hanna Wahl, Marek Dąbrowa, Anna Ostrowska, Malgorzata Kowalska - Parteka, Jaroslaw Pasiński, Arkadiusz Madejczyk
-
Patent number: 11084859Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.Type: GrantFiled: October 24, 2017Date of Patent: August 10, 2021Assignees: Orionis Biosciences BV, VIB VZW, Universiteit GentInventors: Nikolai Kley, Jan Tavernier, Frank Peelman, Lennart Zabeau
-
Patent number: 10948497Abstract: A proteomic expression platform to identify age-related sepsis risk is disclosed using patients with an intra-abdominal infection. A semi-quantitative plasma proteomics workflow was applied which incorporated tandem immuno affinity depletion, iTRAQ labeling, strong cation exchange fractionation, and nanoflow-liquid chromatography coupled to high resolution mass spectrometry. A protein profile was determined that exhibit statistically significant differences in expression levels amongst patients with severe sepsis as a function of age. Representative pathways that are differentially-expressed include, but are not limited to, acute phase response, coagulation signaling, atherosclerosis signaling, lipid metabolism, and production of nitric oxide/reactive oxygen species.Type: GrantFiled: October 8, 2018Date of Patent: March 16, 2021Assignee: The University of Pittsburgh—the Commonwealth of Higher EducationInventors: John A. Kellum, Zhiyun Cao, Derek Angus, Sachin Purushottam Yende, Rena Angilena Sowell Robinson
-
Patent number: 10857152Abstract: Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.Type: GrantFiled: April 23, 2018Date of Patent: December 8, 2020Assignees: TRUSTEES OF BOSTON UNIVERSITY, VIRACTA THERAPEUTICS, INC.Inventors: Ronald J. Berenson, Douglas V. Faller
-
Patent number: 10857145Abstract: The present disclosure provides methods and compositions for the treatment, identification, diagnosis, and prognosis of dystonia, or dystonia related disorders.Type: GrantFiled: September 29, 2016Date of Patent: December 8, 2020Assignee: DUKE UNIVERSITYInventors: Nicole Calakos, Zachary F. Caffall, Joseph Rittiner
-
Patent number: 10813908Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin.Type: GrantFiled: October 22, 2018Date of Patent: October 27, 2020Assignee: CMPD Licensing, LLCInventor: Jay Richard Ray, II
-
Patent number: 10800815Abstract: The present disclosure provides compounds that selectively bind and inhibit potassium channel Kv1.3.Type: GrantFiled: February 21, 2019Date of Patent: October 13, 2020Assignee: Select ION Therapeutics GMBHInventors: Andreas Klostermann, Jörg Stockhaus
-
Patent number: 10729713Abstract: The present invention relates to a pharmaceutical composition for treating hepatitis, liver fibrosis, and liver cancer, which comprises the following components in parts by weight: 0.15-10 parts of vinegar-baked bupleurum root polysaccharides or bupleurum root polysaccharides and 0.05-5 parts of a drug for treating hepatitis.Type: GrantFiled: March 24, 2017Date of Patent: August 4, 2020Assignee: GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINEInventors: Ruizhi Zhao, Ya Zhao, Lijuan Liu
-
Patent number: 10632186Abstract: A novel method for preventing or treating an infectious disease in a subject in need thereof. In particular the method includes the administration of a combination, pharmaceutical combination, medicament or kit-of-parts having a first part including a CD8 vaccine specific for at least one infectious disease-related antigen, a second part including an agent neutralizing circulating alpha interferon and/or an agent blocking interferon alpha signaling, and/or a third part including a type III interferon and/or an agent stimulating the production of type III interferon.Type: GrantFiled: March 21, 2019Date of Patent: April 28, 2020Assignee: 21C BioInventor: Daniel Zagury
-
Patent number: 10624968Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: GrantFiled: January 5, 2018Date of Patent: April 21, 2020Assignee: BICYCLERD LIMITEDInventors: Gavin Bennett, Daniel Paul Teufel
-
Patent number: 10508153Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: June 18, 2015Date of Patent: December 17, 2019Assignee: Amgen Fremont Inc.Inventors: Richard F. Weber, Xiao Feng, Orit Foord, Larry L. Green, Jean M. Gudas, Bruce A. Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose R. F. Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal Singh Kang, Chadwick Terence King, Scott L. Klakamp, Qiaojuan Jane Su
-
Patent number: 10464882Abstract: The present invention discloses a Y-type discrete polyethylene glycol derivative, which has the advantages of determined molecular weights and the number of chain segments, and can avoid the defect of heterogeneity of a PEG derivative. In addition, the Y-type discrete polyethylene glycol derivative of the present invention may increase the water solubility of the discrete polyethylene glycol, and solve the problem of insufficient water solubility of the discrete polyethylene glycol-modified insoluble drug caused by an increase of the loading capacity.Type: GrantFiled: October 23, 2017Date of Patent: November 5, 2019Assignee: JENKEM TECHNOLOGY CO., LTD. (BEIJING)Inventors: Hui Zhu, Meina Lin, Xiaomeng Chen, Zhen'gang Zhu, Xuan Zhao
-
Patent number: 10414816Abstract: The present invention relates to a method for purifying an immunoglobulin, and more particularly, to a method for purifying an immunoglobulin, which comprises: dissolving immunoglobulin-containing plasma protein fraction I+II+III or fraction II+III; adding caprylate to the solution to cause precipitation; performing dialysis and concentration after removal of the precipitate; performing anion exchange resin and ceramic cation exchange resin purification processes to effectively remove a solvent and detergent added to inactivate viruses; and performing elution while maintaining salt concentration at a constant level to maintain the immunoglobulin polymer content at a low level.Type: GrantFiled: March 11, 2014Date of Patent: September 17, 2019Assignee: GREEN CROSS HOLDINGS CORPORATIONInventors: Dong-Hwarn Park, Ki-Hwan Son, Kang Yun Seo, Sung Min Choi, Gun Sul Lee, Ki-Yong Kim
-
Patent number: 10413491Abstract: The present invention relates to a composition for the in vivo degradation of polysaccharide-containing fillers by radical degradation. The composition of the invention comprising at least one source of oxygen free radicals and at least one catalyst of oxygen free radical generation from the at least one source of oxygen free radicals. The present invention further relates to methods and uses of said composition for filler correction or reversal.Type: GrantFiled: April 1, 2015Date of Patent: September 17, 2019Assignee: MERZ PHARMA GMBH & CO. KGAAInventors: Lubin Belkovi, Franck Villain, Andreas Krause, Colin Drabe
-
Patent number: 10336788Abstract: The described invention provides a method for treating myocardial infarction (MI) in a subject comprising administering to the subject a therapeutic amount of a pharmaceutical composition comprising a polypeptide of amino sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof made from a fusion between a first polypeptide that is a cell permeable protein (CPP) selected from the group consisting of a polypeptide of amino acid sequence YARAAARQARA (SEQ ID NO: 2), WLRRIKAWLRRIKA (SEQ ID NO: 21), WLRRIKA (SEQ ID NO: 22), YGRKKRRQRRR (SEQ ID NO: 23), FAKLAARLYR (SEQ ID NO: 25), and KAFAKLAARLYR (SEQ ID NO: 26), and a second polypeptide that is a therapeutic domain (TD), and a pharmaceutically acceptable carrier. The described invention also provides a kit comprising a composition comprising at least one MK2 inhibitor peptide; a means for administering the composition; and a packaging material.Type: GrantFiled: April 17, 2014Date of Patent: July 2, 2019Assignee: MOERAE MATRIX, INC.Inventors: Cynthia Lander, Colleen Brophy, Cam Patterson
-
Patent number: 10273278Abstract: The present invention discloses a fragment of peptide which can be utilized in patients suffering from a disseminated mycobacterial infection. The fragment of peptide contains a sequence of amino acids with seven residues as formula (I) shown below, wherein X1 is Leucine (Leu); X2 is Proline (Pro); X3 is Glutamate (Glu); X4 is serine (Ser); X5 is Serine (Ser); X6 is Leucine (Leu) and X7 is Arginine (Arg): X1-X2-X3-X4-X5-X6-X7 (I).Type: GrantFiled: June 17, 2016Date of Patent: April 30, 2019Assignee: CHANG GUNG UNIVERSITYInventors: Cheng-Lun Ku, Chia-Hao Lin, Chih-Yu Chi, Han-Po Shih, Jing-Ya Ding
-
Patent number: 10208014Abstract: The invention relates to valproic acid derivatives or pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of valproic acid derivatives, and methods for treating or preventing neurological disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, bipolar disorder, migraine, schizophrenia, depression, Alzheimer's disease, cancer, HIV and familial adenomatous polyposis.Type: GrantFiled: November 5, 2014Date of Patent: February 19, 2019Assignee: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula
-
Patent number: 9889180Abstract: The present invention relates to a pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitor and an enhancer of interferon-gamma receptor activity. The invention also relates to method of treating a patient having cancer, comprising administration of the pharmaceutical composition.Type: GrantFiled: November 19, 2013Date of Patent: February 13, 2018Assignee: Agency for Science, Technology and ResearchInventors: Qiang Yu, Zhen Ning Wee
-
Patent number: 9873671Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.Type: GrantFiled: September 27, 2016Date of Patent: January 23, 2018Assignee: NOVIRA THERAPEUTICS, INC.Inventors: George D. Hartman, Scott Kuduk
-
Patent number: 9862926Abstract: The present invention provides methods, kits, and compositions for reducing an innate immune system response in a human or animal cell, tissue or organism. One embodiment comprises: introducing an Agent mRNA comprising in vitro-synthesized mRNA encoding one or more proteins that affect the induction, activity or response of an innate immune response pathway; whereby, the innate immune response in the cell, tissue or organism is reduced compared to the innate immune response in the absence of the Agent mRNA. Other embodiments are methods, compositions and kits for using an Agent mRNA for treating a disease or medical condition in a human or animal that exhibits symptoms of an elevated innate immune system, or for reducing an innate immune response that is induced in a human or animal cell, tissue or organism by a Foreign Substance that is administered to the cell, tissue or organism.Type: GrantFiled: June 27, 2012Date of Patent: January 9, 2018Assignee: CellScript, LLC.Inventors: Cynthia Chin, Anthony D. Person, Gary A. Dahl
-
Patent number: 9763922Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.Type: GrantFiled: November 25, 2015Date of Patent: September 19, 2017Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu
-
Patent number: 9717648Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, daclizumab (ZENAPAX®).Type: GrantFiled: April 23, 2014Date of Patent: August 1, 2017Assignee: Corning IncorporatedInventors: Wendell P. Weeks, Robert Anthony Schaut, Steven Edward DeMartino, John Stephen Peanasky
-
Patent number: 9707229Abstract: The present application relates to compounded compositions, methods of making compounded compositions, kits comprising compounded compositions, containers comprising compounded compositions, and methods of using compounded compositions. The present application also relates to anti-infective agents and methods of using anti-infective agents. For example, disclosed herein are compounded compositions comprising an anti-bacterial agent, an anti-fungal agent, and an excipient base and methods of using a compounded composition to treat or prevent a bacterial infection, a fungal infection, or both, or a suspected bacterial infection, a suspected fungal infection, or both. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: December 18, 2015Date of Patent: July 18, 2017Assignee: CMPD LICENSING, LLCInventor: Jay Richard Ray, II
-
Patent number: 9572814Abstract: Methods of improving the pharmacokinetics of doxepin in a patient.Type: GrantFiled: October 16, 2012Date of Patent: February 21, 2017Assignee: Pernix Sleep, Inc.Inventors: Cara Baron Casseday, Elizabeth Ludington, Michael Skinner, Susan E. Dubé, Roberta L. Rogowski, Philip Jochelson, Robert Mansbach
-
Patent number: 9464128Abstract: The present invention relates to site-specific PEGylated linear salmon calcitonin analogs, or pharmaceutically acceptable salts thereof, process for their preparation, pharmaceutical compositions comprising them, and their use for the preparation of a medicament for the treatment or prevention of diseases associated with bone metabolism, e.g., osteoporosis.Type: GrantFiled: June 4, 2008Date of Patent: October 11, 2016Assignee: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A.Inventors: Keliang Liu, Jiankun Qie, Zhixia Yang, Yuanjun Liang, Ying Wang, Zehui Gong, Huajin Dong
-
Patent number: 9381230Abstract: The invention relates to the field of medicine. Among others, it relates to biologically active analogs of interferons (IFNs) which show less unwanted side-effects and to the therapeutic uses thereof. Provided is an IFN analog, wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and wherein the analog comprises a signaling moiety capable of mediating intracellular IFN activity, said signaling moiety being provided at its N-terminus, optionally via a linker, with at least one targeting domain capable of binding to a cell surface receptor other than the IFN receptor.Type: GrantFiled: December 30, 2010Date of Patent: July 5, 2016Assignee: BiOrion Technologies, B.V.Inventors: Klaas Poelstra, Jai Prakash, Eleonora Beljaars, Ruchi Bansal
-
Patent number: 9302008Abstract: This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000 D.Type: GrantFiled: October 31, 2007Date of Patent: April 5, 2016Assignee: Allergan, Inc.Inventor: Terrence J. Hunt
-
Patent number: 9249182Abstract: Disclosed herein are compositions and methods for purifying antibody products from a sample matrix. In particular, the present invention relates to compositions and methods for purifying antibody products employing hydrophobic interaction chromatography media. In certain embodiments, the invention provides a method for reducing process-related impurities (e.g., host cell proteins), as well as product-related substances, including molecular weight variants (e.g., aggregates and fragments of the antibody product).Type: GrantFiled: March 14, 2013Date of Patent: February 2, 2016Assignee: AbbVie, Inc.Inventors: Matthew Omon Herigstad, Linda E. Rich, Stephen Ming-teh Lu, Natarajan Ramasubramanyan
-
Patent number: 9248110Abstract: Compositions and methods for treating and preventing cancer, particularly lung cancer, lymphangioleiomyomatosis and asthma are provided.Type: GrantFiled: September 12, 2012Date of Patent: February 2, 2016Inventor: Steven Lehrer
-
Patent number: 9192621Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, provided herein are compounds according to Formula 1001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, Y, Z, A, RC and RD are as described herein.Type: GrantFiled: September 26, 2013Date of Patent: November 24, 2015Assignee: IDENIX PHARMACEUTICALS LLCInventors: Benjamin Alexander Mayes, Adel M. Moussa
-
Patent number: 9169212Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.Type: GrantFiled: October 10, 2014Date of Patent: October 27, 2015Assignee: Novira Therapeutics, Inc.Inventors: George D. Hartman, Scott Kuduk
-
Patent number: 9150636Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?, TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.Type: GrantFiled: September 22, 2009Date of Patent: October 6, 2015Assignee: Fox Chase Cancer CenterInventor: Kerry S. Campbell
-
Publication number: 20150132258Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.Type: ApplicationFiled: November 14, 2014Publication date: May 14, 2015Inventor: George D. Hartman
-
Publication number: 20150132217Abstract: The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for Trop-2 (EGP-1) and at least one binding site for CD3. The bispecific antibodies are of use for inducing an immune response against a Trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. The methods may comprising administering the bispecific antibody alone, or with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-?), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of Trop-2+ cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.Type: ApplicationFiled: January 20, 2015Publication date: May 14, 2015Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi, Diane Rossi
-
Publication number: 20150125423Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.Type: ApplicationFiled: January 12, 2015Publication date: May 7, 2015Inventors: Jennifer Mitcham, Matthew Moyle
-
Publication number: 20150110736Abstract: An embodiment of the present invention is a method for subjecting a hematopoetic cell to a JAK/STAT inhibitor, determining the activity of gain-of-function mutations of a Jak family kinase, determining the expression levels and activity of JAK/STAT regulatory proteins, correlating the expression levels and the activity of JAK/STAT regulatory proteins with the activity of gain-of-function mutations of a Jak family kinase and with a response to the JAK/STAT inhibitor, and then classifying the cells. A further embodiment of the invention includes determining the clinical outcome based on the cell classification, determining a method of treatment, determining dosing and scheduling of at least one of the JAK/STAT inhibitors or other compounds.Type: ApplicationFiled: June 3, 2014Publication date: April 23, 2015Applicant: Nodality, Inc.Inventors: Wendy J. FANTL, Alessandra CESANO, Todd COVEY
-
Publication number: 20150098897Abstract: Compositions and methods are provided for cancer treatments. The methodology entails, for instance, administering to a cancer patient a first composition comprising a plurality of bacterially derived intact minicells or intact killed bacterial cells, each of which encompasses an anti-neoplastic agent and carries a bispecific ligand on the surface, the ligand having specificity for a mammalian cell component, and a second composition comprising interferon-gamma (IFN-gamma) or an agent that increases the expression of IFN-gamma in the subject. The compositions include the first composition and the second composition as described, optionally with additional anti-neoplastic agents.Type: ApplicationFiled: October 3, 2014Publication date: April 9, 2015Applicant: EnGenelC Molecular Delivery Pty LtdInventors: Himanshu BRAHMBHATT, Jennifer MACDIARMID
-
Publication number: 20150080940Abstract: Described are embolization devices which carry M1 macrophage promoting agents and/or M2 macrophage inhibiting agents, as well as methods for their manufacture and use. An illustrative embolization device of the disclosure comprises an embolic body and one or more M1 macrophage promoting agents and/or M2 macrophage inhibiting agents carried by a surface of the embolic body. In certain embodiments the embolic body of the present disclosure comprises an embolic coil or an embolic bead.Type: ApplicationFiled: August 27, 2014Publication date: March 19, 2015Inventor: Colleen Gemborys
-
Publication number: 20150079032Abstract: The invention relates to therapy and methods of applying the therapy to a patient. The invention includes the introduction of immature dendritic cells into the patient and the introduction of anti-TNF antibody into the patient. The immature dendritic cells are introduced intratumorally and/or through vessel and the anti-TNF antibody is introduced intratumorally and/or through vessel and/or subcutaneously. The immature dendritic cells can be formed by collecting monocyte cells from the patient and culturing the cells in a culture medium. The invention can be effective to regress, reduce or eliminate tumor cells in tumor tissue of the patients, including metastasized tumors. Further, the treatment of the invention is effective in the absence of conventional therapy, such as radiotherapy and chemotherapy.Type: ApplicationFiled: November 21, 2014Publication date: March 19, 2015Applicant: HASUMI INTERNATIONAL RESEARCH FOUNDATIONInventor: KENICHIRO HASUMI
-
Publication number: 20150079034Abstract: The present invention provides recombinant Listeria strains comprising an angiogenic factor, recombinant polypeptides comprising an angiogenic factor operatively linked to a polypeptide comprising a PEST-like sequence, recombinant nucleotide molecules encoding same, related vaccines, and immunogenic and therapeutic methods utilizing same.Type: ApplicationFiled: June 13, 2014Publication date: March 19, 2015Inventors: Matthew SEAVEY, Yvonne Paterson, Paulo Maciag, Duane Sewell